Christopher McCabe

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 283 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer

Fiona Collinson, David Jayne, Alessio Pigazzi et al. · International Journal of Colorectal Disease · 2011 · 255 citations

Medicine, Oncology, Surgery +17

Value based pricing for NHS drugs: an opportunity not to be missed?

Karl Claxton, Andrew Briggs, Martin Buxton et al. · BMJ · 2008 · 232 citations · Full text

Management, Business Economics, Pharmaceutical Policy +14

Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines

George Q. Daley, Insoo Hyun, Jane F. Apperley et al. · Stem Cell Reports · 2016 · 225 citations · Full text

Pharmacy, Cell Biology, Translational Sciences +16

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others

John M.S. Bartlett, Jane Bayani, Andrea Marshall et al. · JNCI Journal of the National Cancer Institute · 2016 · 215 citations · Full text

Medicine, Biostatistics, Oncology +13